tbuckley/cabot-search huggingface dataset:
Abstract IA05: PDX in colorectal cancer and carcinoma of the anal canal
Authors: Virginie Dangles-Marie
Journal: Clinical Cancer Research (2016)

Abstract Through 2 examples of digestive tumors, (colorectal cancer, “CRC”, and anal squamous cell carcinoma, “ASCC”), we will present the development and use of patient-derived tumor xenografts. Colorectal cancer remains a major cause of mortality worldwide and CRC patient death is generally attributable to metastasis development. By contrast, ASCC is a rare tumor (&amp;lt; 5% of all lower gastrointestinal tract malignancies in Europe) but with increasing incidence and mutilating surgery for patients with chemoradiotherapy-resistant tumors. Consequently, these both digestive tumors require new therapeutic approaches and relevant preclinical models to identify and test new drugs/combinations. In this context, we develop and characterize patient-derived CRC and ASCC xenografts. We will illustrate the capacity of these PDXs to recapitulate the intratumoral clonal heterogeneity, gene expression profile, key molecular alterations, histology and drug response of the patient tumors through passages in mice. In addition to these now well-known features depicted in a large number of tumor types, we will discuss about practical situations (orthotopic engraftment, impact of mouse host, criteria for measuring drug efficacy). Finally, we will report alternative methods as ex vivo tumor spheres we have developed. Citation Format: Virginie Dangles-Marie. PDX in colorectal cancer and carcinoma of the anal canal. [abstract]. In: Proceedings of the AACR Special Conference: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; Feb 11-14, 2016; New Orleans, LA. Philadelphia (PA): AACR; Clin Cancer Res 2016;22(16_Suppl):Abstract nr IA05.
Influence of Human Leukocyte Antigen Haplotypes on Acute Graft Versus Host Disease Incidence after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Sameer Gupta, Charu Aggarwal, Philip L. McCarthy, Swaminathan Padmanabhan, Minoo Battiwalla, Theresa E. Hahn
Journal: Blood (2006)
A Randomized, Controlled Trial of Varying D-Dimer Cutpoints According to Clinical Pretest Probability Compared with a Uniform D-Dimer Cutpoint for Diagnosis of Deep Vein Thrombosis
Authors: Lori Ann Linkins, Shannon M. Bates, Susan Kahn, Eddy Lang, Jim Julian, Jeffrey S. Ginsberg, Jim D Douketis, Sam Schulman, Clive Kearon
Journal: Blood (2010)
Erratum: Corrigendum: Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization
Authors: Andrew R Cullinane, Anna Straatman-Iwanowska, Andreas Zaucker, Yoshiyuki Wakabayashi, Christopher K Bruce, Guanmei Luo, Fatimah Rahman, Figen Gürakan, Eda Utine, Tanju B Özkan, Jonas Denecke, Jurica Vukovic, Maja Di Rocco, Hanna Mandel, Hakan Cangul, Randolph P Matthews, Steve G Thomas, Joshua Z Rappoport, Irwin M Arias, Hartwig Wolburg, A S Knisely, Deirdre A Kelly, Ferenc Müller, Eamonn R Maher, Paul Gissen
Journal: Nature Genetics (2011)
Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma
Authors: Changchun Deng, Mark Lipstein, Xavier Jirau Serrano, Michael Mangone, Luigi Scotto, Owen A O'Connor, Peter Sportelli, Hari P. Miskin, Srikant Viswanadha
Journal: Blood (2014)
The Wandering Mesenteric Lymph Node
Authors: Lucia Zanoni, Maurizio Zompatori, Federica Scalorbi, Stefano Fanti, Valentina Ambrosini
Journal: Clinical Nuclear Medicine (2017)

A patient multiple endocrine neoplasia type 1 presenting with radiological suspicion of pancreatic neuroendocrine tumor relapse after surgical and somatostatin analog treatment underwent restaging Ga-DOTANOC PET/CT. Standard and delayed images detected an area of focal intense uptake moving from the left para-aortic to the paracaval region. The lesion was identified at previous imaging in different abdominal locations (eg, adjacent to the duodenal wall at presurgical PET and in the aortocaval region at restaging contrast-enhanced CT). Dual time-point Ga-DOTANOC PET/CT was crucial to accurately diagnose the wandering mesenteric lymph node, a potential interpretation pitfall especially when found far from the initial position.
Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition.
Authors: Rachel Wuerstlein, Karl Sotlar, Oleg Gluz, Daniel Hofmann, Burkhard Otremba, Raquel Von Schumann, Isabelle Witzel, Christian Schindlbeck, Wolfgang Janni, Chrisitan Schem, Ingo Bauerfeind, Stephan Hasmueller, Hans Tesch, Axel Paulenz, Pascale Morel, Wayne Cowens, John Hornberger, Ronald E. Kates, Enrico Pelz, Nadia Harbeck
Journal: Journal of Clinical Oncology (2015)

535 Background: Prosigna is a standardized test measuring expression levels of 50 classifier genes (PAM50) in formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue using nCounter Technology (NanoString Technologies, Inc., Seattle, WA). It provides intrinsic subtype and risk of recurrence (ROR) score predicting 10y recurrence probability. It was retrospectively validated by ABCSG 8 and TransATAC. WSG BCIST evaluates its impact on systemic therapy decisions in EBC. Methods: 201 consecutive postmenopausal pts. with ER+ HER2- N0 were recruited (11 centers; 10/2013-10/2014). Primary objective was to assess impact of Prosigna vs. standard immunohistochemistry (IHC) on adjuvant chemotherapy recommendations and actual therapy received. Secondary objectives include physicians’ confidence in recommendations, patients’ decisional conflict, and rate of chemotherapy-related adverse events. Prosigna testing was performed centrally (university) and repeated de-centrally (community-based pathology) for quality control. Results: Intrinsic subtypes were highly concordant (95.5%) between the two pathologies. Risk group differed in only 1/9 discordant cases; underlying tumor heterogeneity is being evaluated. In the total cohort (198 patients evaluated), 58.1% of tumors were classified by PAM50 as Luminal A, 39.9% as Luminal B, 1.5% Basal, 0.5% HER2-E. Local IHC classified 18.3% of PAM50 Luminal A as Luminal B, and 39.2% PAM50 Luminal B as luminal A (overall 26.9% discordance). Prosigna results led to a reported change in chemotherapy (CT) indication in 19.2% overall, including 39.2% of PAM50 luminal B patients. Actual CT use and morbidity will be evaluated after scheduled 6-month follow-up. Conclusions: In the WSG BCIST prospective decision impact study, Prosigna results led to a 19% change in chemotherapy indication. The 27% discordance in intrinsic subtyping between PAM50 and IHC underlines the importance of molecular testing for optimal systemic therapy indications in EBC. As a pre-planned pooled analysis, WSG BCIST can later be evaluated together with two similar studies currently ongoing in Europe. Clinical trial information: NCT01974856.
A phase II, single-arm, efficacy and safety study of poziotinib (NOV120101) in Korean patients with advanced or metastatic lung adenocarcinoma who have acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Authors: Ji-Youn Han, Jin Soo Lee, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eun Kyung Cho, Young Joo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung-Ho Nam, Jong Hee Han, Jung Yong Kim, Jina Jung
Journal: Journal of Clinical Oncology (2015)

8085 Background: Poziotinib is an oral irreversible inhibitor of EGFR, HER2 and HER4, and has shown preclinical activity in lung cancer models with EGFR mutations including T790M. This phase II study was aimed to access the efficacy of poziotinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to erlotinib or gefitinib. Methods: Eligible patients had documented activating EGFRmutations and developed acquired resistance after treatment with erlotinib or gefitinib based on Jackman criteria. Patients received poziotinib at a dose of 16 mg once daily in 28-day cycles. The primary endpoint was PFS. All tumor responses were evaluated by independent review and, in a supportive manner, by investigator. Results: A total of 39 patients were treated with poziotinib in this study (29 women, median age 62 years [range, 43-84]). Most patients received erlotinib or gefitinib as first-line (n = 27) or second-line therapy (n = 11). The median time on erlotinib or gefitinib was 13.1 months (range, 3.4-33.2). Genotyping using tumor biopsy acquired at study entry was determined in 37 patients; 19 patients had EGFR T790M mutation, 2 PIK3CA mutation and no MET-amplification. Partial response with poziotinib was confirmed in 3 patients (8%; 95% CI, 2-21). Twenty patients (51%; 95% CI, 35-68) had disease control of at least stable disease for ≥ 8 weeks. The median PFS and overall survival were 2.7 (95% CI, 1.8-3.7) and 15.0 months (95% CI, 9.5-not estimable), respectively. The most frequently reported AEs of grade 3 by preferred term were rash (59%), stomatitis (18%), and diarrhoea (10%). Two patients were discontinued due to treatment-related AEs (one grade 3 rash and one grade 3 myositis). Conclusions: Poziotinib showed modest efficacy in patients with EGFR-mutant lung adenocarcinoma who had progressed on erlotinib or gefitinib. Obvious clinical evidence suggesting that poziotinib may overcome acquired resistance secondary to EGFR T790M mutation was not captured in this study. Clinical trial information: NCT01718847.
Significance of Minimal Residual Disease (MRD) by Multiparameter Flow Cytometry (MFC) In Adults with De Novo Acute Lymphoblastic Leukemia (ALL) After Therapy with the Modified Hyper-CVAD Regimen
Authors: Deborah A. Thomas, Susan O'Brien, Jeffrey Jorgensen, Sa A. Wang, Stefan Faderl, William G. Wierda, Rebecca Garris, Michael Andreeff, Jorge E. Cortes, Hagop Kantarjian
Journal: Blood (2010)
Conflicts of Interest for Patient-Advocacy Organizations
Authors: Matthew S. McCoy, Michael Carniol, Katherine Chockley, John W. Urwin, Ezekiel J. Emanuel, Harald Schmidt
Journal: New England Journal of Medicine (2017)

In this examination of 104 large patient-advocacy organizations, 83% receive financial support from drug, device, and biotechnology companies, and industry executives often serve on governing boards. The authors recommend more transparency about industry involvement.
Microfluidic Networks: Thin, Soft, Skin-Mounted Microfluidic Networks with Capillary Bursting Valves for Chrono-Sampling of Sweat (Adv. Healthcare Mater. 5/2017)
Authors: Jungil Choi, Daeshik Kang, Seungyong Han, Sung Bong Kim, John A. Rogers
Journal: Advanced Healthcare Materials (2017)

Jungil Choi, John A. Rogers, and co-workers describe a “skin-like” microfluidic platform that bonds to the skin, collects, and stores sweat in a time sequenced set of chambers in article number 1601355. Pressure induced by the sweat glands drives flow through a network of microchannels that incorporate capillary bursting valves for passively guiding sweat through different reservoirs in the system in sequential fashion.
Abstract IA18: Noncoding RNA biomarkers in gastrointestinal cancers
Authors: Ajay Goel
Journal: Cancer Research (2017)

Abstract Cancer has emerged as a leading cause of mortality worldwide, claiming over 8 million lives annually. Gastrointestinal (GI) cancers account for ~35% of these mortalities. Recent advances in diagnostic and treatment strategies have reduced mortality among GI cancer patients, yet a significant number of patients still develop late-stage cancer, where treatment options are inadequate. Emerging interests in “liquid biopsies” have encouraged investigators to identify and develop clinically-relevant noninvasive genomic and epigenomic signatures that can be exploited both as biomarkers capable of detecting premalignant and early-stage cancers, and as therapeutics for targeted cancer treatment. In this context, microRNAs (miRNAs), which are small non-coding RNAs that are frequently dysregulated in cancers have emerged as promising entities for development as liquid biopsy biomarkers. Albeit the future looks promising, current approaches for detecting miRNAs in blood and other biofluids remain inadequate. This presentation will summarize an update on exploiting circulating miRNAs as cancer biomarkers and evaluating their potential as tissue-based, and more importantly as liquid biopsies in GI cancers. Citation Format: Ajay Goel. Noncoding RNA biomarkers in gastrointestinal cancers. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr IA18.
Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients
Authors: Terrence Neal Wong, Jeffery M. Klco, Ryan Demeter, Christopher A. Miller, Allegra Petti, Nichole Havey, Robert Fulton, Sharon Heath, Elaine R Mardis, Peter Westervelt, John F. DiPersio, Matthew J. Walter, John S. Welch, Timothy Graubert, Richard K Wilson, Timothy J. Ley, Daniel C. Link
Journal: Blood (2015)
An air-fluid level in the cavity is the sign of the exacerbation in chronic pulmonary aspergillosis
Authors: Yohei Yatagai, Takehumi Saito, Yasuhiro Umetsu, Shimao Fukai
Journal: European Respiratory Journal (2011)

Background:  We have experienced a lot of chronic pulmonary aspergillosis (CPA) cases showing exacerbation associated with change of intracavitary air-fluid levels during the development process. It seems very possible that appearances and disappearances of air-fluid levels are related to exacerbation of CPA. But it has yet to be determined.   Aims and objectives:  To demonstrate relationship between air-fluid levels and acute exacerbation of CPA.   Method:  We analyzed retrospectively our patients with acute exacerbation of CPA during the period from 2001 to 2010 at Ibarakihigashi National Hospital.   Results:  We experienced 93 cases of acute exacerbation of CPA and the incidence of appearance of air-fluid level was 34% (32 patients). At deterioration, new infiltrative shadows appeared on separate sites from primary cavities in 33 patients (35%), and 27 of them previously had air-fluid levels in their cavities. In 15 patients, fluid volume in their cavities increased before acute exacerbation. Eight of them showed new infiltrations away from primary lesions and fluid volume in their cavities decreased after acute exacerbation. Corticosteroids drastically improved their infiltrations on chest radiograph, blood findings and medical conditions in 5 out of 8. But in 3patients, corticosteroids didn9t improve their conditions.   Conclusion:  The air-fluid levels in cavities were associated with acute exacerbation of CPA. In some cases, patients showed new infiltrations away from cavities with decreased fluids during acute exacerbation. It suggested that fluids in cavities, which contained substances produced by  Aspergillus , might damage separate sites from primary cavities.
Antigen-responsive molecular sensor enables real-time tumor-specific imaging
Authors: Hyunjin Kim, Hak Soo Choi, Seok-Ki Kim, Byung Il Lee, Yongdoo Choi
Journal: Theranostics (2017)

Antibody-fluorophore conjugates have high potential for the specific fluorescence detection of target cancer cells in vitro and in vivo.However, the antibody-fluorophore conjugates described to date are inappropriate for real-time imaging of target cells because removal of unbound antibody is required to reduce background fluorescence before quantifiable analysis by microscopy.In addition, clinical applications of the conjugates have been limited by persistent background retention due to their long systemic circulation and nonspecific uptake.Here we report fast and real-time near-infrared fluorescence imaging of target cancer cells using an antigen-responsive molecular "on-off" sensor: the fluorescence of trastuzumab-ATTO680 conjugate is dark (i.e., turned off) in the extracellular region, while it becomes highly fluorescent (i.e., turned on) upon binding to the target antigen HER2 on cancer cell surface.This molecular switch enables fast and real-time imaging of target cancer cells in vitro and in vivo.
Engraftment Kinetics After Alimtuzumab-Based Allogeneic Stem Cell Transplant (SCT): Full Donor T-Cell Chimerism Did Not Predict for Acute Graft Versus Host Disease (GVHD) or CMV Reactivation
Authors: Henry C. Fung, Muhammed Alikhan, Lela Buckingham, John J. Maciejewski, Reem Karmali, Kent W Christopherson, Elizabeth Shima Rich, Parameswaran Venugopal, Stephanie A. Gregory, Sunita Nathan
Journal: Blood (2012)
Relationships of Serum Ferritin, Transferrin Saturation, and HFE Mutations and Self-Reported Diabetes Mellitus in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.
Authors: Ronald T. Acton, James C. Barton, Leah Passmore, Paul C. Adams, Mark R. Speechley, Fitzroy W. Dawkins, Phyliss Sholinsky, David M. Reboussin, Gordon D. McLaren, Emily L. Harris, Thomas C. Bent, Thomas Vogt, Oswaldo Castro
Journal: Blood (2005)
High Efficiency Transduction of Human Mesenchymal Stem Cells Using Retroviral Gene Transfer with Triple Reporter Genes.
Authors: Ting Niu, Amer M. Najjar, Simon N. Robinson, Hong Yang, William K. Decker, John D. McMannis, Jingjing Ng, Michael W. Thomas, Dongxia Xing, Richard E. Champlin, Juri G. Gelovani, Elizabeth J. Shpall
Journal: Blood (2004)
Abstract B16: The detection of ductal carcinoma using noninvasive hyperspectral imaging
Authors: Yasser Khouj, Jeremy Dawson, James Coad, Linda Vona-Davis
Journal: Cancer Research (2017)

Abstract Introduction: Hyperspectral imaging (HSI) technology is an optical medical imaging modality that has great potential for noninvasive tissue analysis in breast cancer. This imaging method may be able to enhance the detection of cancer tissue and lead to advances in the optical diagnosis of patients. Objective: The goal of this study was to use high resolution hyperspectral imaging microscopy to differentiate marked biopsies of normal and breast cancer tissues. Methods: For our hyperspectral imaging platform, we obtained stained (n=10) and unstained (n=10) pathology slides from ductal carcinomas of the breast and compared them. To capture the HSI, we used a hyperspectral camera that generates a spectral cube containing the spectra of each pixel between 460 to 640 nm and normalized the data to a gray scale to maximize data stability. The spectral signatures were graphed using MATLAB software. Results: The system was able to detect a clear spectral difference between cancer and normal tissues in hematoxylin and eosin stained slides. The spectrum of cancer tissue had a relatively lower intensity than that of normal tissue in the wavelength range between 480 and 610 nm. Conclusions: Our preliminary study showed a clear hyperspectral snapshot differentiating normal breast tissue from ductal carcinoma. Further HSI and quantitative analysis will demonstrate the feasibility of using this new imaging technique in breast cancer. Citation Format: Yasser Khouj, Jeremy Dawson, James Coad, Linda Vona-Davis. The detection of ductal carcinoma using noninvasive hyperspectral imaging. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B16.
Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis
Authors: Fabrice Uhel, Imane Azzaoui, Murielle Grégoire, Céline Pangault, Joelle Dulong, Jean-Marc Tadié, Arnaud Gacouin, Christophe Camus, Luc Cynober, Thierry Fest, Yves Le Tulzo, Mikael Roussel, Karin Tarte
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Sepsis induces a sustained immune dysfunction responsible for poor outcome and nosocomial infections. Myeloid-derived suppressor cells (MDSCs) described in cancer and inflammatory processes may be involved in sepsis-induced immune suppression, but their clinical impact remains poorly defined.To clarify phenotype, suppressive activity, origin, and clinical impact of MDSCs in patients with sepsis.Peripheral blood transcriptomic analysis was performed on 29 patients with sepsis and 15 healthy donors. A second cohort of 94 consecutive patients with sepsis, 11 severity-matched intensive care patients, and 67 healthy donors was prospectively enrolled for flow cytometry and functional experiments.Genes involved in MDSC suppressive functions, including S100A12, S100A9, MMP8, and ARG1, were up-regulated in the peripheral blood of patients with sepsis. CD14posHLA-DRlow/neg monocytic (M)-MDSCs were expanded in intensive care unit patients with and without sepsis and CD14negCD15pos low-density granulocytes/granulocytic (G)-MDSCs were more specifically expanded in patients with sepsis (P < 0.001). Plasma levels of MDSC mediators S100A8/A9, S100A12, and arginase 1 were significantly increased. In vitro, CD14pos- and CD15pos-cell depletion increased T-cell proliferation in patients with sepsis. G-MDSCs, made of immature and mature granulocytes expressing high levels of degranulation markers, were specifically responsible for arginase 1 activity. High initial levels of G-MDSCs, arginase 1, and S100A12 but not M-MDSCs were associated with subsequent occurrence of nosocomial infections.M-MDSCs and G-MDSCs strongly contribute to T-cell dysfunction in patients with sepsis. More specifically, G-MDSCs producing arginase 1 are associated with a higher incidence of nosocomial infections and seem to be major actors of sepsis-induced immune suppression.
Plasmacytoid Precursor Dendritic Cells Contribute to the Ability of CD8+TCR− Facilitating Cells Population of Enhance Hematopoetic Stem Cell Engraftment and HSC Clonogenicity.
Authors: Isabelle J. Fugier, Francine Rezzoug, Yiming Huang, Carrie L. Schanie, Suzanne T. Ildstad
Journal: Blood (2004)
Who Is the Better Donor for Young Hematopoietic Transplant Recipients without Siblings: An Older-Aged Haploidentical Parental Donor or a Young Unrelated Donor?
Authors: Mingming Zhang, Yi Luo, Yamin Tan, Jimin Shi, Weiyan Zheng, Yanmin Zhao, Zhen Cai, He Huang
Journal: Blood (2016)
Peripherally Inserted Central Catheterization in Patients Receiving Long Term Chemotherapy: A Tertiary Cancer Centre Experience Form Eastern India
Authors: Somnath Datta, Pinki Chandra, Nita Biswas, Subhashis Dey, Sukanta Koner, Ashis Mukhopadhyay, Soma Mukhopadhyay
Journal: Blood (2008)